NBIX

Neurocrine Biosciences, Inc. Press Releases

$24.49
*  
0.59
2.47%
Get NBIX Alerts
*Delayed - data as of Dec. 19, 2014  -  Find a broker to begin trading NBIX now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Neurocrine Biosciences Announces Expansion of its Clinical Pipeline
12/10/2014 8:00:00 AM - PR Newswire
▲23.62 % Price Change since this news event. The Volume Ratio is 3.27.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Neurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference
12/4/2014 7:00:00 PM - PR Newswire
▲27.29 % Price Change since this news event. The Volume Ratio is 1.54.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Neurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare Conference
11/25/2014 1:00:00 PM - PR Newswire


Neurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference
11/12/2014 1:56:00 PM - PR Newswire
▲28.42 % Price Change since this news event. The Volume Ratio is 0.23.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Neurocrine Biosciences, Inc. Announces Appointment of Darin Lippoldt as Chief Legal Officer
11/4/2014 7:30:00 AM - PR Newswire
▲34.93 % Price Change since this news event. The Volume Ratio is 0.83.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Neurocrine Biosciences to Present at the Nomura Biotechnology Conference
11/3/2014 7:00:00 PM - PR Newswire
▲34.93 % Price Change since this news event. The Volume Ratio is 0.81.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Neurocrine Biosciences Reports Third Quarter 2014 Results
11/3/2014 4:01:00 PM - PR Newswire
▲34.93 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Neurocrine Biosciences Receives Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia
10/30/2014 7:30:00 AM - PR Newswire
▲34.34 % Price Change since this news event. The Volume Ratio is 1.8.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2014 Financial Results
10/27/2014 4:05:00 PM - PR Newswire
▲38.83 % Price Change since this news event. The Volume Ratio is 2.22.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Neurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854
10/20/2014 4:05:00 PM - PR Newswire
▲49.33 % Price Change since this news event. The Volume Ratio is 0.72.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study
10/2/2014 4:02:00 PM - PR Newswire


Neurocrine Biosciences, Inc. Announces Appointment of Malcolm Lloyd-Smith as Chief Regulatory Officer
10/1/2014 5:20:00 PM - PR Newswire